NRX-101 (D-Cycloserine + Lurasidone) , a Qualified Infectious Disease Product, is Active Against Drug-Resistant Urinary Pathogens In Vitro
M. T. Sapko, M. Manyak, R. Panicucci, J. C. Javitt
This study evaluates NRX-101, a combination of D-Cycloserine and lurasidone, against drug-resistant urinary pathogens in vitro, showing DCS's antibacterial activity and lurasidone's lack of interference.
bioRxiv · Jan 14, 2024 · PreprintMicrobiology